HomeAI · summaries
Storia in 2 fonti
AstraZeneca’s rare disease drug Ultomiris misses main goal in late-stage trial
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest in a series of setbacks this year that have fuelled concerns about the drugmaker’s pipeline.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
AstraZeneca’s rare disease drug Ultomiris misses main goal in late-stage trial
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest…
- ·
endpoints.news
AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare disease
AstraZeneca posts Q2 pipeline setbacks: mixed ADC data in gastric cancer, an Ultomiris TMA trial miss and an Imfinzi liver cancer failure.